Press & news

June 23rd 2021 - Press Release

Investment company EMERAM sells its portfolio company MEONA to Trill Impact

Funds advised by EMERAM Capital Partners, one of the leading investment companies for medium-sized companies in the German-speaking region (“EMERAM”), sell their portfolio company MEONA to the private equity firm Trill Impact.

MEONA is considered an innovation leader for clinical software. Numerous university clinics and hospitals use the software to digitalise and optimise hospital processes. Thereby, MEONA contributes to improving the quality of medical treatment and patient care. The company was formed in 2017 under the leadership of EMERAM as a combination of the healthcare IT companies Meona GmbH and bvba and was expanded in 2019 with the acquisition of Dr. Heni Software GmbH & Co. KG. Since then, MEONA has continuously extended its product portfolio through own developments and has successfully driven its internationalisation. Given the strong growth in past years, the number of employees doubled to more than 140.

Kai Köppen, Senior Partner at EMERAM Capital Partners, explains: “Together we have developed MEONA over the past years. Today, the company is a leading provider of software solutions for hospitals. As business development partner, EMERAM has supported MEONA in its strategic positioning and the continuous development of the organisation. We have now found an ideal partner for the next growth phase of the company, as Trill Impact is also acquiring i-SOLUTIONS Health GmbH, with whom MEONA has already been in contact for some time. Subject to the relevant antitrust approvals, this will create another strong player in the healthcare IT market. We welcome this step and support it accordingly with our sale.”

PD Dr. med. Tobias Schäfer, CEO of MEONA, adds: “MEONA has benefited substantially from EMERAM's support which has enabled us to make the best possible use of the market opportunities arising from the ongoing digitalisation in healthcare and to expand our market position. Together with EMERAM, we have developed MEONA from a specialist in patient charting and medication software to a leading clinical workspace provider. We are well positioned to benefit from the opportunities offered by the Hospital Future Act (“KHZG”), which has come into force in October 2020, and for which we offer numerous solutions that will further accelerate MEONA's growth. Together with our new owner, we want to continue our successful course.”
The purchase price is subject to confidentiality. EMERAM was advised by Jones Day, PWC and GCA Altium on this transaction.